MEG3 and type 2 diabetes mellitus: Data generated from genome-wide DNA methylation profiling studies along with mechanistic work on the dysregulation of DNA methylation of key regulatory pathways (such as the imprinted DLK1-MEG3 locus in T2D), is likely to inspire the development of novel therapeutic approaches for augmenting beta cell function and mass.